OHR is focused on the development of novel therapeutics for the treatment of serious and unmet medical needs in the ophthalmology space. Their lead program is Squalamine eye drops for the treatment of the wet form of age-related macular degeneration (wet AMD) and other ophthalmic neovascularization disorders. Wet AMD is a leading cause of vision loss and blindness in the elderly population, affecting over 1.75 million patients in the United States alone. The program is in a Phase II clinical trial with interim data expected in the second quarter of 2014.

Read More